Geneos Wealth Management Inc. EAGG — ISHARES TR

Ownership history in Geneos Wealth Management Inc.  ·  5 quarters on record

AI Ownership Summary

Geneos Wealth Management Inc. reported ISHARES TR (EAGG) in 5 quarterly 13F filings from 2024 Q3 through 2025 Q3. The latest visible filing shows EAGG at 0.00% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this EAGG ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Geneos Wealth Management Inc.'s position in ISHARES TR, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q3

EAGG was reported at 0.00% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.0% in 2024 Q3

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q3 to 2025 Q3

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

EAGG stock page Geneos Wealth Management Inc. fund profile Geneos Wealth Management Inc. full holdings
How Geneos Wealth Management Inc. held EAGG — position size vs. price
% of Fund (quarterly)    EAGG price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 5 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q3 REDUCED 66.2% +1.2% ❌ 246 -482 -66.2% 0.00% $12K 2025-10-22 $47.38
2025 Q2 ADDED — — — 728 +728 — 0.00% $35K 2025-08-18 $45.97
2025 Q1 REDUCED 100.0% +1.1% ❌ — -610 -100.0% 0.00% $37K 2025-05-08 $44.99
2024 Q4 ADDED — — — 610 +20 +3.4% 0.00% $28K 2025-01-21 $44.30
2024 Q3 INITIATED — — — 590 — — 0.00% $29K 2024-11-14 $44.13

🏢 Other funds also holding EAGG

As of 2026 Q1 — sorted by position size

Joel Adams & Associates, Inc. 7.88% Olde Wealth Management, LLC 3Y 6.93% INVESTMENT COUNSEL CO OF NEVADA 5.67% Avise Financial Cooperative, Inc. 4.68% eCIO, Inc. 3.16% Atlantic Private Wealth, LLC 3Y 2.93% Sensenig Capital Advisors, Inc 2.86% Archer Investment Management, LLC 2.73% rebel Financial LLC 2.69% BLUESTEM FINANCIAL ADVISORS, LLC 3Y 2.55%

FAQ About Geneos Wealth Management Inc. and EAGG

These are the practical questions this page is built to answer before you even open the full history table.

How long has Geneos Wealth Management Inc. reported owning EAGG?

Geneos Wealth Management Inc. reported EAGG across 5 quarterly 13F filings, from 2024 Q3 through 2025 Q3.

What was the largest reported EAGG position in Geneos Wealth Management Inc.'s portfolio?

The largest reported portfolio weight for EAGG was 0.00% in 2024 Q3.

What is the latest reported EAGG position on this page?

The most recent filing on this page is 2025 Q3, when Geneos Wealth Management Inc. reported 246 shares, equal to 0.00% of portfolio, with an estimated market value of $12K.

What does the chart on this EAGG ownership page compare?

The chart compares Geneos Wealth Management Inc.'s quarterly EAGG portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Geneos Wealth Management Inc. time their EAGG position?

Based on 13F filing dates vs. subsequent EAGG price moves, Geneos Wealth Management Inc. correctly timed 3 out of 4 reported position changes (75%). The annualised alpha on EAGG relative to SPY over the holding period was -6.1%.

← Back to Geneos Wealth Management Inc. Holdings